Associated tags: Human, Animal, Boehringer Ingelheim, Animal Health, Pharmaceutical industry, Health, Patient, Research
Locations: SPAIN, DELAWARE, FLORIDA, PENNSYLVANIA, UNITED STATES OF AMERICA, MASSACHUSETTS, ITALY, USA, PHILADELPHIA, EUROPEAN UNION, EU, SWITZERLAND, CANADA, LONDON, GB, TOKYO, INDIA, ENGLAND, MISSOURI, UNITED STATES, NORTH AMERICA, ILLINOIS, CONNECTICUT, INGELHEIM AM RHEIN, DE, III, II, GERMANY, EUROPE, KENYA, FRANCE, BRAZIL, UNITED KINGDOM, JAPAN, GEORGIA
Seizure,
Afoxolaner,
Human,
Tick,
Tremor,
Argyreia nervosa,
Diarrhea,
Hypersalivation,
Breeding,
Veterinarian,
Farmer,
Health,
Ataxia,
Parasitism,
DSM-IV codes,
Livestock,
Coccidioides immitis,
Animal Health,
History,
Boehringer Ingelheim,
Vomiting,
Animal,
Patient,
Lethargy,
Dog,
Itch,
Eprinomectin,
Pet,
Parasitic disease,
COMBO,
FDA,
Praziquantel,
Veterinary medicine,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Safety,
DVM,
Food,
Boehringer Ingelheim Animal Health,
Cat,
Pharmaceutical industry,
Fine chemical,
Medical device,
Dipylidium caninum It is the first-and-only feline broad-spectrum protection against fleas, ticks, roundworms, hookworms, heartworm disease and tapeworms.
Key Points:
- It is the first-and-only feline broad-spectrum protection against fleas, ticks, roundworms, hookworms, heartworm disease and tapeworms.
- NexGard® COMBO is a one-and-done, monthly topical solution, specially formulated for feline patients, that helps make compliance easy.
- To further enable compliance, veterinarians can prescribe 3-dose and 6-dose presentations to best support the needs of their feline patients.
- Together, NexGard® COMBO brings monthly one-and-done, broad-spectrum protection against internal and external parasites — that includes tapeworms — to cats for the first time.
TEANECK, N.J., April 11, 2023 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) announced it is working with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to advance the speed and quality of medicinal therapy development. Leveraging the Veeva (NYSE: VEEV) Development Cloud, Cognizant will help Boehringer Ingelheim to unify medicinal development processes and data into a connected technology ecosystem, enhancing collaboration across clinical, regulatory, and quality functions.
Key Points:
- Leveraging the Veeva (NYSE: VEEV) Development Cloud, Cognizant will help Boehringer Ingelheim to unify medicinal development processes and data into a connected technology ecosystem, enhancing collaboration across clinical, regulatory, and quality functions.
- "Achieving an end-to-end platform to help speed the development of life-changing therapies has been an elusive goal for many organizations, and we're making that vision a reality," said Uli Brӧdl, Senior Vice President, Global Clinical Development at Boehringer Ingelheim.
- "Our collaborations with Cognizant and Veeva are empowering us to advance this important program that will positively impact patient lives."
- By bringing together Boehringer Ingelheim's clinical, regulatory, and quality functions onto this unified platform simultaneously, this holistic approach is expected to increase interoperability and operational efficiencies.
TEANECK, N.J., April 11, 2023 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) announced it is working with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to advance the speed and quality of medicinal therapy development. Leveraging the Veeva (NYSE: VEEV) Development Cloud, Cognizant will help Boehringer Ingelheim to unify medicinal development processes and data into a connected technology ecosystem, enhancing collaboration across clinical, regulatory, and quality functions.
Key Points:
- Leveraging the Veeva (NYSE: VEEV) Development Cloud, Cognizant will help Boehringer Ingelheim to unify medicinal development processes and data into a connected technology ecosystem, enhancing collaboration across clinical, regulatory, and quality functions.
- "Achieving an end-to-end platform to help speed the development of life-changing therapies has been an elusive goal for many organizations, and we're making that vision a reality," said Uli Brӧdl, Senior Vice President, Global Clinical Development at Boehringer Ingelheim.
- "Our collaborations with Cognizant and Veeva are empowering us to advance this important program that will positively impact patient lives."
- By bringing together Boehringer Ingelheim's clinical, regulatory, and quality functions onto this unified platform simultaneously, this holistic approach is expected to increase interoperability and operational efficiencies.
Retrieved on:
Wednesday, March 29, 2023
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Acceleration,
Ingelheim am Rhein,
Heart failure,
Diabetes,
Executive officer,
Flea,
Tax,
Finance,
Medicine,
Animal Health,
Inflammation,
Boehringer Ingelheim,
EUR,
Animal,
Patient,
Investment,
Dog,
Cat,
Growth,
FDA,
Research and development,
Mental health,
Idiopathic pulmonary fibrosis,
Pharmaceutical industry,
Fine chemical Boehringer Ingelheim today reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, while deepening investments in the search for new treatments.
Key Points:
- Boehringer Ingelheim today reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, while deepening investments in the search for new treatments.
- Boehringer Ingelheim received one Breakthrough Designation, three Fast Track Designations, and two Orphan Drug Designations from the FDA.
- OFEV® generated net sales of 3.2 billion EUR, representing a currency-adjusted growth of 20.6 percent in 2022.
- Looking ahead, Boehringer Ingelheim anticipates moderate growth in 2023, on a comparable basis, with a slight increase in its operating income, creating the fundamentals for bringing more innovative medicines to patients and animals.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Skin,
Kidney,
Flare,
Multimedia,
GPP,
Safety,
Heart failure,
Plaque,
Boehringer Ingelheim,
Patient,
Disease EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular psoriasis (GPP) up to 48 weeks.1,2 Safety data were in line with previously conducted clinical trials with spesolimab.
Key Points:
- EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular psoriasis (GPP) up to 48 weeks.1,2 Safety data were in line with previously conducted clinical trials with spesolimab.
- This press release features multimedia.
- View the full release here: https://www.businesswire.com/news/home/20230129005023/en/
“Painful GPP flares can occur suddenly, escalate quickly, and may require urgent hospital care leaving people anxious and uncertain about what the future might hold,” said Carinne Brouillon, Member of the Board of Managing Directors, responsible for Human Pharma, Boehringer Ingelheim.
- “The EFFISAYIL™ 2 results reinforce the potential of spesolimab to prevent GPP flares, giving patients the power to plan their lives, regardless of their disease.
Retrieved on:
Thursday, January 26, 2023
Idiopathic pulmonary fibrosis,
HIV disease progression rates,
FVC,
Boehringer Ingelheim,
RESP,
IPF,
Pulmonary fibrosis,
Vital capacity,
COPD,
FDA,
Research,
Patient,
Wheeze,
Disease,
Cough,
Asthma,
Pharmaceutical industry,
Medical imaging PHILADELPHIA, Jan. 26, 2023 /PRNewswire/ -- Strados Labs today announced a collaboration with Boehringer Ingelheim to remotely monitor patients using its FDA-cleared pulmonary wearable device in an upcoming idiopathic pulmonary fibrosis (IPF) pilot study. In Boehringer Ingelheim's pilot study, the Strados RESP Biosensor will be used to monitor cough and crackles in IPF patients at home aiming to accelerate the development of much needed new therapies for people living with IPF.
Key Points:
- PHILADELPHIA, Jan. 26, 2023 /PRNewswire/ -- Strados Labs today announced a collaboration with Boehringer Ingelheim to remotely monitor patients using its FDA-cleared pulmonary wearable device in an upcoming idiopathic pulmonary fibrosis (IPF) pilot study.
- In Boehringer Ingelheim's pilot study, the Strados RESP Biosensor will be used to monitor cough and crackles in IPF patients at home aiming to accelerate the development of much needed new therapies for people living with IPF.
- Research has suggested that cough may be associated with worse outcomes in pulmonary fibrosis.
- "Currently, disease progression in IPF is measured by a decline in forced vital capacity (FVC)," Says Strados Labs CEO & Cofounder Nick Delmonico.
LLY,
Safety,
The New England Journal of Medicine,
Tablet,
Boehringer Ingelheim,
III,
Medical Affairs Bureau,
Standard of care,
New Drug Application,
Regulation of tobacco by the U.S. Food and Drug Administration,
EMPA,
Diabetes,
ARR,
Kidney disease,
Cardiovascular disease,
Shanda,
NYSE,
CKD,
Heart failure,
Type 2 diabetes,
Hospital,
Kidney,
Eli Lilly and Company,
FDA,
Urine,
SGLT2,
Chronic kidney disease,
EGFR,
Patient,
Diet,
Exercise,
Risk,
Food,
ASN,
Dietary supplement,
Pharmaceutical industry,
Nephrology,
Empagliflozin RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 20, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.
Key Points:
- RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 20, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.
- Results were presented during the American Society of Nephrology (ASN)'s Kidney Week 2022 and simultaneously published in The New England Journal of Medicine.
- Jardiance is also indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
- In March 2020, the FDA granted Fast Track designation to the clinical investigation of Jardiance to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.
Retrieved on:
Tuesday, January 17, 2023
Professional Services,
Mental Health,
Health,
Other Professional Services,
Human Resources,
Finance,
General Health,
Attention,
Human,
Mental health,
Human resources,
Certification,
Family,
Friends,
Environment,
Mental disorder,
Boehringer Ingelheim,
Mental,
Medicine Boehringer Ingelheim’s employer offerings do particularly stand out in the dimensions of wellbeing, work environment, as well as rewards and recognition.
Key Points:
- Boehringer Ingelheim’s employer offerings do particularly stand out in the dimensions of wellbeing, work environment, as well as rewards and recognition.
- The results reflect the company’s holistic employee healthcare and wellbeing approach that, beyond its emphasis on mental health, integrates concepts of physical, social and financial health.
- The Global Top Employers award acknowledges that,” says Dr Sven Sommerlatte, Global Head of Human Resources at Boehringer Ingelheim.
- Boehringer Ingelheim strives to curb the stigma often experienced by people with mental health conditions as an employer and beyond.
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
Cancer,
TCR,
Partnership,
Ingelheim am Rhein,
Boehringer Ingelheim,
Patient,
Research,
T cell,
Antigen,
Library,
Vaccine Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs.
Key Points:
- Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs.
- Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients.
- “On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences.
- Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
Boehringer Ingelheim,
Antigen,
Partnership,
T cell,
TCR,
Research,
Multimedia,
Lightspeed Venture Partners,
Immunotherapy,
Patient,
Animal Health,
Therapy,
Library,
Fine chemical,
Vaccine,
Pharmaceutical industry,
Cancer Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients.
Key Points:
- Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients.
- Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer," said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
- "On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments," said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences.
- Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
